Boston Scientific (NYSE:BSX) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Boston Scientific (NYSE:BSX) announced its earnings results on Wednesday. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01, FiscalAI reports. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific updated its Q2 2026 guidance to 0.820-0.840 EPS and its FY 2026 guidance to 3.340-3.410 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Q1 results were strong: organic sales grew 9.4% and adjusted EPS was $0.80 (up 6%), with an adjusted operating margin of 28%, at the high end of guidance.
• Management lowered 2026 guidance, now targeting 6.5%–8% organic growth (Q2 guide 5%–7%) and adjusted EPS of $3.34–$3.41, citing unanticipated headwinds in key franchises.
• CHAMPION‑AF delivered favorable results (all primary and secondary endpoints), which the company expects will support label updates, guideline/NCD considerations, and long‑term expansion of the WATCHMAN population.
• Near‑term pressure in EP and Urology: EP saw greater-than-expected share erosion amid intensifying competition and PolarX/ACURATE discontinuations affected EMEA, while Urology underperformed in stone management and sacral neuromodulation.
• Capital moves and M&A: Boston Scientific expects the Penumbra deal to close in H2 2026 (pending approvals) and added $4B to its repurchase program, planning to repurchase about $2B of shares in Q2, signaling active capital return and tuck‑in M&A focus.

Boston Scientific Stock Down 3.4%

Shares of BSX stock traded down $2.24 during trading hours on Friday, hitting $63.45. 3,975,868 shares of the company were exchanged, compared to its average volume of 16,125,805. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific has a one year low of $59.38 and a one year high of $109.50. The business’s 50-day simple moving average is $68.71 and its two-hundred day simple moving average is $86.02. The stock has a market capitalization of $94.30 billion, a price-to-earnings ratio of 26.54, a P/E/G ratio of 1.03 and a beta of 0.78.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat and strong sales growth drove upside momentum as investors viewed the guidance reset as a prudent reset and a potential buying opportunity. Boston Scientific (NYSE:BSX) Shares Up 9.4% on Strong Earnings
• Positive Sentiment: Accelerated short‑term bullish activity: traders bought an unusually high volume of call options after the earnings print, indicating speculative/hedged upside bets. Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)
• Neutral Sentiment: Multiple analysts lowered price targets but largely kept buy/outperform ratings — the revisions temper near‑term upside but signal continued confidence in long‑term fundamentals. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Some banks called the guidance cut “prudent” and expect a Q2 trough, framing the reset as near‑term noise rather than a structural issue. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Management trimmed 2026 profit and revenue guidance, which is the primary driver of downward revisions and near-term uncertainty about growth pacing. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple law firms have filed or issued investor alerts about a securities‑class action covering July 23, 2025–Feb 3, 2026 and are soliciting lead plaintiffs (May 4 deadline), adding legal risk and headline pressure. BSX Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Boston Scientific Corporation Securities Class Action
• Negative Sentiment: Shares have tested new 52‑week lows following analyst cuts and heightened uncertainty, reflecting short‑term risk aversion. Boston Scientific (NYSE:BSX) Hits New 52-Week Low After Analyst Downgrade

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.34% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC boosted its stake in Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after acquiring an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management boosted its stake in Boston Scientific by 4.7% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 139 shares during the period. Manhattan West Asset Management LLC boosted its stake in Boston Scientific by 8.3% in the second quarter. Manhattan West Asset Management LLC now owns 2,302 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 176 shares during the period. Reynders McVeigh Capital Management LLC boosted its stake in Boston Scientific by 6.3% in the third quarter. Reynders McVeigh Capital Management LLC now owns 3,099 shares of the medical equipment provider’s stock valued at $303,000 after acquiring an additional 185 shares during the period. Finally, HM Payson & Co. boosted its stake in Boston Scientific by 3.0% in the fourth quarter. HM Payson & Co. now owns 6,892 shares of the medical equipment provider’s stock valued at $657,000 after acquiring an additional 198 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on BSX shares. JPMorgan Chase & Co. lowered their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Robert W. Baird lowered their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research note on Thursday. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Mizuho lowered their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Finally, Citigroup lowered their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.